BAI1 treatment was shown to have no or slightly positive effect in increasing the level of insoluble TDP-43 protein (Fig. 4A), suggesting that it is not a promising candidate to follow up for neurodegenerative disease treatment. Here, ADGRB1 is linked to neurodegenerative disease.